Our experts led by Dr Dusan Ninkov PhD invented the best solutions for worldwide clinical medicine problems.
Experienced and dedicated pharmacists and bioscientists care about development.
The production and distribution of our products is controlled by TeslaBioscienceTM team.
Conducting wide range research and development for novel medicine, providing it for worldwide trials followed by global registration and production is our pathway to bring new values in science and lives. RnD for humankind, to serve health.
From a global perspective, infectious diseases are the second leading cause of death and the leading cause of disability. Nosocomial infectious diseases are the major cause of tragically complex infectious diseases in the 21st century, in both developed and developing nations.
Current antibiotic therapy for nosocomial infections is also facing worsening antimicrobial resistance. The number of new antibiotics made to combat resistant infectious bacterias have declined over the years.
Current antibiotics such as penicillin, oxacillin, methicillin and macrolide-based antibiotics also treat bacterial infections but are powerless against microbes, which have developed a resistance against these traditional therapies.
Currently, there are incredible challenges for developing new antibiotic therapies that address this and other infectious diseases. The global medical community is constantly in search of new pharmaceutical products to protect the lives of patients around the globe.
More…
US Patent No.: 6,921,539 B2
US Patent No.: 12,037,302 B1
EP Patent No.: EP 1 482 791 A1
EP Patent Pending No.: EP 4 067 336 A1
USPTO Trademark Pending
No.: 90604023 and 90604027
EUIPO Trademark Pending
No.: 018460867
On the 16th of June, 2024, Tesla Bioscience was granted the USPTO patent…
